Natco Pharma Approves Letter of Offer for Rights Issue
Natco Pharma's Fund-Raising Committee approved the Letter of Offer for a Rights Issue. The issue involves up to 17,058,082 shares at ₹750 each, aiming to raise ₹12,794 million (₹1,279.4 crore). The ratio is 2 shares for every 21 held on the Record Date of October 1, 2026. The issue opens October 12 and closes October 22, 2026.
A rights issue can dilute existing shareholder value but also provides capital for future growth. The impact is medium as it's a significant fundraising activity for the company.
The company is actively raising capital through a rights issue, which indicates a positive step for growth and expansion, approved by the committee and regulatory bodies.
Natco Pharma Limited announced that its Fund-Raising Committee has approved the Letter of Offer for a Rights Issue.
The committee meeting, held on September 25, 2026, commenced at 8:15 p.m. and concluded at 8:45 p.m. The company has also obtained ISIN: INE987B20018 for the Rights Entitlements.
The Rights Issue involves up to 17,058,082 fully paid-up equity shares of face value ₹2 each, offered at a price of ₹750 per share, including a premium of ₹748. This aims to raise up to ₹12,794 million (approximately ₹1,279.4 crore). The ratio for the issue is 2 rights equity shares for every 21 equity shares held as of the Record Date, which is October 1, 2026. The issue is scheduled to open on October 12, 2026, and close on October 22, 2026.
The company has received in-principle approvals from NSE and BSE for the listing of the Rights Equity Shares, with NSE designated as the stock exchange for the issue. The Letter of Offer dated September 28, 2026, has been submitted to SEBI.
What to do with a filing like this
Natco Pharma Limited filed this with the NSE as a statutory disclosure, categorised under rights issue. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Natco Pharma Limited. Read the original for the full detail.